- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Intermountain Healthcare | Strategic Alliance Partners
Intermountain Healthcare is a team of more than 41,000 caregivers who serve the healthcare needs of people across the Intermountain West, primarily in Utah, Idaho, and Nevada. We are an integrated, not-for-profit health system based in Salt Lake City, Utah, with clinics, a medical group, affiliate networks, hospitals, homecare, telehealth, health insurance plans, and other services, along with wholly owned subsidiaries including SelectHealth, Saltzer Health, and Intermountain Healthcare in Nevada.
Connect with us:
Latest from Intermountain Healthcare
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
April 11, 2024
Video
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Unmet Needs Surrounding mCRC Treatment
April 11, 2024
Video
Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
Data Surrounding Treatment for MSI-high Patients from ASCO 2024
April 04, 2024
Video
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
April 04, 2024
Video
Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
March 28, 2024
Video
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Considerations for Platinum-based Therapy
March 28, 2024
Video
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
March 21, 2024
Video
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
March 21, 2024
Video
Side effect profiles driven by fruquintinib use are discussed.
Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician
March 14, 2024
Podcast
Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.
Consideration for Fruquintinib Dosing and Titration
March 14, 2024
Video
Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
March 14, 2024
Video
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
March 07, 2024
Video
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
FRESCO-2 Study Highlights
March 07, 2024
Video
Medical experts provide key takeaways and impacts from the FRESCO-2 study.
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
February 29, 2024
Video
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Fruquintinib MoA and Toxicity Profile Overview
February 29, 2024
Video
Key safety considerations for the use of fruquintinib are explored.
Evaluating 3L Treatment Landscape Evolution
February 22, 2024
Video
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Overview of Current mCRC Treatment Landscape
February 22, 2024
Video
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
GI Cancer Research Lends Insight Into the Future of Chemotherapy Combinations and Sequencing
July 24, 2023
Article
Mark Lewis, MD, discusses the contested designs of the NorPACT-1 trial and NAPOLI 3 trial; where trastuzumab deruxtecan falls in the HER2-positive metastatic colorectal cancer treatment paradigm; and how the PROSPECT trial results can improve quality of life for patients with rectal cancer.